Skip to main content

Table 4 Pertussis-antigen-specific IgG GMC in infants at birth, 2, 5 and 13 months of age

From: A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants

   Maternal TdaP3-IPV Maternal TdaP5-IPV Unvaccinated mothers TdaP5-IPV:DTaP3-IPV TdaP3-IPV:none TdaP5-IPV:none
Antigen Time point N GMC (95% CI) N GMC (95% CI) N GMC (95% CI) GMR (95% CI) GMR (95% CI) GMR (95% CI)
PT Birth 57 50.06 (37.55–66.75)a 53 35.84 (26.73–48.05)    0.72 (0.48–1.07)   
2 months 61 16.82 (12.64–22.37) 70 10.7 (8.07–14.18) 27 2.64 (1.77–3.94) 0.64 (0.43–0.94) 6.36 (3.82–10.61) 4.05 (2.45–6.68)
5 months 62 30.72 (26.32–35.84) 65 33.55 (28.89–38.96) 45 43.2 (35.5–52.58) 1.09 (0.88–1.35) 0.71 (0.56–0.9) 0.78 (0.61–0.98)
13 months 61 5.07 (3.95–6.51) 63 6.05 (4.56–8.01) 44 6.56 (4.79–9.00) 1.19 (0.82–1.73) 0.77 (0.51–1.16) 0.92 (0.62–1.38)
5:2 months 60 1.89 (1.33–2.69) 65 3.25 (2.29–4.62) 27 14.1 (8.67–22.93) 1.72 (1.05–2.81) 0.13 (0.07–0.25) 0.23 (0.12–0.43)
FHA Birth 57 245.79 (190.72–316.76) 53 97.44 (78.44–121.03)    0.4 (0.29–0.55)   
2 months 61 66.37 (51.95–84.79) 70 31.74 (26.05–38.68) 27 5.97 (4.02–8.87) 0.48 (0.35–0.65) 11.12 (7.36–16.79) 5.32 (3.55–7.96)
5 months 62 54.52 (47.75–62.25) 65 50.67 (43.92–58.45) 45 67.31 (55.02–82.34) 0.93 (0.77–1.13) 0.81 (0.65–1.01) 0.75 (0.6–0.94)
13 months 61 14.01 (11.25–17.43) 63 18.07 (13.81–23.64) 44 22.2 (17.15–28.72) 1.29 (0.92–1.81) 0.63 (0.44–0.91) 0.81 (0.57–1.17)
5:2 months 60 0.83 (0.65–1.05) 65 1.67 (1.3–2.15) 27 10.37 (6.31–17.04) 2.02 (1.43–2.84) 0.08 (0.05–0.13) 0.16 (0.1–0.26)
PRN Birth 56 250.13 (160.52–389.77) 52 230.53 (151.1–351.7)    0.92 (0.51–1.68)   
2 months 62 62.51 (39.17–99.75) 70 83.02 (59.29–116.25) 27 2.63 (1.44–4.82) 1.33 (0.76–2.32) 23.73 (11.46–49.15) 31.52 (15.41–64.46)
5 months 62 65.88 (55.66–77.96) 65 53.32 (42.59–66.76) 44 73.85 (54.41–100.22) 0.81 (0.61–1.08) 0.89 (0.64–1.24) 0.72 (0.52–1)
13 months 60 10.47 (8.18–13.42) 63 7.04 (5.33–9.30) 40 11.24 (8.4–15.04) 0.67 (0.47–0.97) 0.93 (0.62–1.39) 0.63 (0.42–0.93)
5:2 months 61 1.06 (0.64–1.75) 65 0.65 (0.45–0.93) 27 26.54 (11.81–59.62) 0.62 (0.34–1.12) 0.04 (0.02–0.09) 0.02 (0.01–0.05)
FIM Birth 56 34.09 (22.77 –51.04) 53 282.36 (177.32–449.62)    8.28 (4.55–15.09)   
2 months 61 9.82 (6.71–14.37) 70 85.5 (59.59–122.67) 27 5.2 (2.94––9.21) 8.71 (5.2 –14.58) 1.89 (0.96–3.71) 16.43 (8.47–31.88)
5 months 62 3.64 (2.77–4.79) 65 18.47 (13.58–25.12) 45 2.32 (1.73–3.12) 5.07 (3.38–7.61) 1.57 (1.02–2.41) 7.95 (5.19–12.16)
13 months 61 1.54 (1.26–1.87) 63 1.49 (1.24–1.79) 44 1.21 (0.92–1.60) 0.97 (0.75–1.26) 1.27 (0.93–1.72) 1.23 (0.91–1.67)
5:2 months 60 0.38 (0.3–0.48) 65 0.22 (0.19–0.26) 27 0.49 (0.33–0.71) 0.58 (0.44–0.76) 0.79 (0.55–1.14) 0.46 (0.32–0.66)
  1. Abbreviations: DdaP3-IPV low dose diphtheria, tetanus, acellular pertussis (three pertussis antigens), inactivated poliovirus, TdaP5-IPV low dose diphtheria, tetanus, acellular pertussis (five pertussis antigens), inactivated poliovirus, GMC geometric mean concentration, CI confidence interval, GMR geometric mean ratio, PT pertussis toxin, FHA filamentous haemagglutinin, FIM fimbriae types 2 and 3, PRN pertactin
  2. aThe GMC of anti-PT IgG was lower than the limit of detection for one infant at birth
  3. Blood samples were not collected at birth from infants born to women not receiving a pertussis-containing vaccine in pregnancy as these women and infants were only recruited in the postnatal period; therefore, corresponding cells are empty